Revenue Growth
Total revenue for fiscal 2025 was $554.0M, up 4% year-over-year; Q4 2025 revenue was a company record $326.2M, up 4% year-over-year.
Material Improvement in Profitability
Full year GAAP net income rose to $40.0M, nearly 4x the prior year (vs $10.1M in 2024); full year adjusted EBITDA increased 40% to $97.3M; Q4 adjusted EBITDA was $132.9M, up 10% year-over-year.
Medicare Segment Strength
Full year Medicare revenue was $531.2M, up 6% year-over-year; Q4 Medicare revenue was $319.6M, up 5% year-over-year; Q4 Medicare gross profit grew 12% to $178.3M and full year Medicare gross profit grew 21%.
Improved LTV and Efficiency
Medicare Advantage LTV increased 11% in Q4 2025; LTV to CAC ratio improved to 2.2x in Q4 from 2.0x a year earlier, indicating better long-term economics and higher enrollment margins.
Record Commissions Receivable
Total commissions receivable at December 31, 2025 were $1.1B, up 12% year-over-year, representing a record high balance and underlying cash-collection potential.
Ancillary Product Momentum
Hospital indemnity plan (HIP) approved application volume surged over 400% year-over-year in Q4; 2025 annual approved HIP members exceeded 30,000 (more than 5x 2024); Medicare Supplement approved applications rose 39% in Q4.
Operational and Cost Discipline
Management implemented actions expected to reduce fixed operating costs by ~$30M in 2026 (~20% lower fixed costs vs 2025) and reduce variable spend by over $60M, targeting overall spend reductions >$90M year-over-year.
AI and Technology Differentiation
An AI screener piloted earlier in the year was scaled during AEP, reducing wait times and performing on par or better than human screeners on transfer rates and conversions, positioning additional AI applications as a competitive advantage.
Capital and Liquidity Actions
Augmented liquidity via a $125M revolving credit facility (net of transaction costs) and repaid $70.7M of existing term loan; year-end cash, equivalents and marketable securities were $77.2M.